Date published: 2025-10-30

1-800-457-3801

SCBT Portrait Logo
Seach Input

RNF103-CHMP3 Inhibitors

Chemical inhibitors of RNF103-CHMP3 can directly interrupt its function through various mechanisms, primarily by disrupting cellular processes and pathways that RNF103-CHMP3 is known to be involved with. Concanamycin A and Bafilomycin A1, for example, target the vacuolar-type H+-ATPase (V-ATPase) which is essential for endosomal acidification. This acidification is a prerequisite for the proper functioning of the endosomal sorting complexes required for transport (ESCRT), to which RNF103-CHMP3 contributes. The inhibition of V-ATPase by these chemicals can impede endosomal function, which in turn can inhibit the activity of RNF103-CHMP3 in membrane remodeling and vesicle formation. Similarly, Dynasore disables the GTPase activity of dynamin, a protein involved in the final scission of newly formed vesicles from the membrane. By impeding this scission, Dynasore can influence the ability of RNF103-CHMP3 to participate in ESCRT-related processes.

Other chemicals target the actin cytoskeleton, which plays a critical role in cellular processes such as membrane remodeling and vesicle trafficking that RNF103-CHMP3 is associated with. ML141, CK-666, SMIFH2, and Cytochalasin D are inhibitors that affect various aspects of actin dynamics. ML141 interferes with CDC42, a small GTPase that regulates actin polymerization. CK-666 acts on the Arp2/3 complex, inhibiting its ability to nucleate actin filaments. SMIFH2 disrupts formin-mediated actin assembly, and Cytochalasin D blocks actin polymerization directly. These disruptions to actin dynamics can impede RNF103-CHMP3's involvement in vesicle formation and trafficking. Additionally, Y-27632 inhibits ROCK, a kinase that influences actin organization, which can also lead to the impairment of RNF103-CHMP3's role in cytoskeletal-dependent cellular processes. PD 98059, a MEK inhibitor, and Wortmannin, a PI3K inhibitor, disrupt signaling pathways that indirectly influence cytoskeletal rearrangements and phosphoinositide dynamics, respectively, which are processes important for RNF103-CHMP3's function. Z-VAD-FMK, by inhibiting caspases, can interfere with apoptotic body clearance, a process where RNF103-CHMP3's ESCRT function is important. Finally, Hydroxychloroquine, by increasing endosomal pH, can impair endosomal sorting, thus potentially inhibiting RNF103-CHMP3's role in the ESCRT machinery. Each chemical, by targeting specific cellular functions, can contribute to the functional inhibition of RNF103-CHMP3.

SEE ALSO...

Items 1 to 10 of 12 total

Display:

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Concanamycin A

80890-47-7sc-202111
sc-202111A
sc-202111B
sc-202111C
50 µg
200 µg
1 mg
5 mg
$65.00
$162.00
$650.00
$2550.00
109
(2)

Inhibits vacuolar-type H+-ATPase (V-ATPase), which is crucial for endosomal acidification, affecting the function of RNF103-CHMP3 in endosomal sorting complexes required for transport (ESCRT).

Bafilomycin A1

88899-55-2sc-201550
sc-201550A
sc-201550B
sc-201550C
100 µg
1 mg
5 mg
10 mg
$96.00
$250.00
$750.00
$1428.00
280
(6)

Specifically inhibits V-ATPase, disrupting endosome function and therefore potentially inhibiting RNF103-CHMP3's role in membrane remodeling and vesicle formation.

Dynamin Inhibitor I, Dynasore

304448-55-3sc-202592
10 mg
$87.00
44
(2)

GTPase inhibitor that impairs the function of dynamin, which is involved in membrane scission, potentially impacting RNF103-CHMP3's role in ESCRT-related processes.

ML 141

71203-35-5sc-362768
sc-362768A
5 mg
25 mg
$134.00
$502.00
7
(1)

CDC42 inhibitor which could disrupt actin cytoskeleton organization, thereby potentially inhibiting RNF103-CHMP3's involvement in membrane remodeling and vesicle trafficking.

CK 666

442633-00-3sc-361151
sc-361151A
10 mg
50 mg
$315.00
$1020.00
5
(0)

Inhibitor of the Arp2/3 complex, which can alter actin polymerization, potentially affecting RNF103-CHMP3's role in cytoskeletal dynamics associated with membrane remodeling.

SMIFH2

340316-62-3sc-507273
5 mg
$140.00
(0)

Inhibits formin-mediated actin assembly, which may impair cytoskeletal rearrangements necessary for RNF103-CHMP3 function in vesicle formation and trafficking.

PD 98059

167869-21-8sc-3532
sc-3532A
1 mg
5 mg
$39.00
$90.00
212
(2)

MEK inhibitor that can disrupt ERK/MAPK signaling, potentially impairing downstream effects on cytoskeletal dynamics that could influence RNF103-CHMP3 activity.

Y-27632, free base

146986-50-7sc-3536
sc-3536A
5 mg
50 mg
$182.00
$693.00
88
(1)

ROCK inhibitor that can disrupt actin cytoskeleton organization, potentially inhibiting RNF103-CHMP3's role in cellular processes dependent on cytoskeletal dynamics.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

PI3K inhibitor that can affect endocytosis and vesicle trafficking, potentially inhibiting RNF103-CHMP3's role in those processes by altering phosphoinositide dynamics.

Z-VAD-FMK

187389-52-2sc-3067
500 µg
$74.00
256
(6)

Pan-caspase inhibitor that can affect apoptotic body clearance, potentially impacting RNF103-CHMP3's role in the ESCRT machinery during this process.